Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) frequently relapses despite new treatments.
• Lenalidomide shows promise, especially for non-germinal center B-cell (non-GCB) DLBCL, but real-world data are limited.

Purpose of the Study:

• To evaluate the efficacy and safety of lenalidomide in a large cohort of relapsed/refractory (R/R) DLBCL patients.
• To compare outcomes based on DLBCL subtype (GCB vs. non-GCB) and lenalidomide dosage.

Main Methods:

• Retrospective analysis of 123 R/R DLBCL patients treated with lenalidomide (15 or 25 mg/day).
• Median follow-up of 4.5 years.
• Assessment of remission rates, response duration, toxicity, progression-free survival, and overall survival.

Main Results:

• Complete remission (CR) and partial remission (PR) rates were significantly higher in non-GCB patients (32% CR, 33% PR) compared to GCB patients (0% CR, 3% PR).
• The 25 mg/day dose showed superior response rates (21% CR, 23% PR) and longer response duration compared to the 15 mg/day dose.
• Toxicity was manageable and reversible; progression-free survival was better in non-GCB patients and with the higher dose.

Conclusions:

• Lenalidomide is a viable and safe treatment for R/R DLBCL with limited, reversible toxicity.
• The drug is more effective in non-GCB DLBCL and at a 25 mg/day dosage.
• Lenalidomide offers a valuable therapeutic option, especially for non-GCB R/R DLBCL patients.